

Boehringer Ingelheim cordially invites you to a presentation



Albuminuria and Cardiovascular Risk: The Power of Early Detection and CKD Diagnosis

Find out why early detection matters – Albuminuria is a key indicator of CV risk in CKD^{1,2}



Featured Guest Speaker

Sheryl Chow, PharmD, FACP, FAHA, FHFSA
Associate Professor of Pharmacy Practice
College of Pharmacy
Western University of Health Sciences, Pomona
Assoc Clinical Professor of Medicine, UC Irvine



Date

11/17/26

Time

6:30PM Arrival, 7:00PM Program Start

RSVP By

Reserve your seat as soon as possible

Rep Name

Carrie Helber: C: (714) 473-7557

Rep Email

carrie.helber@boehringer-ingelheim.com



Program Objectives

Recognize that albuminuria is an important indicator of vascular damage in the cardiorenal system, which can be detected early, serving as a risk predictor and risk multiplier for cardiovascular disease^{1,5}

Discover how albuminuria, detectable through a UACR test, serves as a potentially modifiable marker that can help unveil hidden cardiovascular risk, even in the absence of a decline in eGFR^{1,3,5}

Review the risk of cardiovascular disease in patients with albuminuria, highlighting the urgency of diagnosing CKD early and managing CV risk^{1,2,6}

Apply guideline recommendations for testing albuminuria, in addition to eGFR, in patients with hypertension, diabetes, and others at risk for CKD, and review available resources to support patient care^{1,7-9}



Location

Arroyo Chop House
536 South Arroyo Pkwy
Pasadena, CA 91105

Can't join us?

Scan here to see
what's next on our calendar.



CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio. 1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. *Kidney Int.* 2024;105(4S):S117-S314. 2. Matsushita K et al. *Lancet Diabetes Endocrinol.* 2015;3(7):514-525. 3. Lambers Heerspink HJ, Gansevoort RT. *Clin J Am Soc Nephrol.* 2015;10(6):1079-1088. 4. Beernink JM et al. *Diabetes Obes Metab.* 2025;1-19. doi:10.1111/dom.16359 5. Romero-González G et al. *J Clin Med.* 2024;13(3):777. 6. Yaqoob K et al. *Heart.* 2025;121(11):506-512. 7. Alfego D et al. *Diabetes Care.* 2021;44(9):2025-2032. 8. Jones DW et al. *Hypertension.* 2025;82(10):e212-e316. 9. American Diabetes Association Professional Practice Committee. *Diabetes Care.* 2025;48(suppl 1):S239-S251. doi:10.2337/dc25-S011

This program is open to healthcare practitioners (HCPs) for whom the information presented is relevant to their practice. Pursuant to the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals, attendance by healthcare professionals' spouses or guests is not permitted.

